Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2008 5
2009 5
2010 2
2011 1
2012 1
2013 1
2014 3
2015 7
2016 5
2017 3
2018 12
2019 11
2020 7
2021 16
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

74 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Among authors: cescon dw. Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9. Lancet. 2020. PMID: 33278935 Clinical Trial.
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
Wu Q, Ba-Alawi W, Deblois G, Cruickshank J, Duan S, Lima-Fernandes E, Haight J, Tonekaboni SAM, Fortier AM, Kuasne H, McKee TD, Mahmoud H, Kushida M, Cameron S, Dogan-Artun N, Chen W, Nie Y, Zhang LX, Vellanki RN, Zhou S, Prinos P, Wouters BG, Dirks PB, Done SJ, Park M, Cescon DW, Haibe-Kains B, Lupien M, Arrowsmith CH. Wu Q, et al. Among authors: cescon dw. Nat Commun. 2020 Aug 21;11(1):4205. doi: 10.1038/s41467-020-18020-8. Nat Commun. 2020. PMID: 32826891 Free PMC article.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Adams S, et al. Among authors: cescon dw. Ann Oncol. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517. Ann Oncol. 2019. PMID: 30475950 Free article. Clinical Trial.
Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer.
Deblois G, Tonekaboni SAM, Grillo G, Martinez C, Kao YI, Tai F, Ettayebi I, Fortier AM, Savage P, Fedor AN, Liu X, Guilhamon P, Lima-Fernandes E, Murison A, Kuasne H, Ba-Alawi W, Cescon DW, Arrowsmith CH, De Carvalho DD, Haibe-Kains B, Locasale JW, Park M, Lupien M. Deblois G, et al. Among authors: cescon dw. Cancer Discov. 2020 Sep;10(9):1312-1329. doi: 10.1158/2159-8290.CD-19-1493. Epub 2020 Jun 16. Cancer Discov. 2020. PMID: 32546577 Free article.
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. Adams S, et al. Among authors: cescon dw. Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518. Ann Oncol. 2019. PMID: 30475947 Free article. Clinical Trial.
Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression.
Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, Yung KY, Brenner D, Knobbe-Thomsen CB, Cox MA, Elia A, Berger T, Cescon DW, Adeoye A, Brüstle A, Molyneux SD, Mason JM, Li WY, Yamamoto K, Wakeham A, Berman HK, Khokha R, Done SJ, Kavanagh TJ, Lam CW, Mak TW. Harris IS, et al. Among authors: cescon dw. Cancer Cell. 2015 Feb 9;27(2):211-22. doi: 10.1016/j.ccell.2014.11.019. Epub 2015 Jan 22. Cancer Cell. 2015. PMID: 25620030 Free article.
Novel classes of immunotherapy for breast cancer.
Hernando-Calvo A, Cescon DW, Bedard PL. Hernando-Calvo A, et al. Among authors: cescon dw. Breast Cancer Res Treat. 2022 Jan;191(1):15-29. doi: 10.1007/s10549-021-06405-2. Epub 2021 Oct 8. Breast Cancer Res Treat. 2022. PMID: 34623509 Review.
Gene Expression Analyses in Breast Cancer: Sample Matters.
Haibe-Kains B, Cescon DW. Haibe-Kains B, et al. Among authors: cescon dw. JNCI Cancer Spectr. 2018 May 22;2(2):pky019. doi: 10.1093/jncics/pky019. eCollection 2018 Apr. JNCI Cancer Spectr. 2018. PMID: 31360851 Free PMC article. No abstract available.
Targeting the cell cycle in breast cancer: towards the next phase.
Thu KL, Soria-Bretones I, Mak TW, Cescon DW. Thu KL, et al. Among authors: cescon dw. Cell Cycle. 2018;17(15):1871-1885. doi: 10.1080/15384101.2018.1502567. Epub 2018 Sep 11. Cell Cycle. 2018. PMID: 30078354 Free PMC article. Review.
74 results